PMID- 1409010
OWN - NLM
STAT- MEDLINE
DCOM- 19921026
LR  - 20190818
IS  - 0196-9781 (Print)
IS  - 0196-9781 (Linking)
VI  - 13
IP  - 2
DP  - 1992 Mar-Apr
TI  - Pharmacological characterization of angiotensin II binding sites in the canine 
      pancreas.
PG  - 313-8
AB  - High affinity 125I-angiotensin II (Ang II) binding sites were characterized in 
      the canine pancreas. Total binding increased with protein concentration and 
      equilibrium was reached within 60-90 min at 22 degrees C. Specific binding was 
      saturable and averaged 70% of total. Scatchard analysis of binding yielded a KD 
      of 0.48 +/- 0.18 nM with a Bmax of 32.8 +/- 6.5 fmol/mg protein (mean +/- SEM, n 
      = 6). The addition of the reducing agent dithiothreitol increased specific 
      binding two-fold. The rank order of displacement of 125I-Ang II binding by native 
      angiotensin peptides was Ang II greater than or equal to Ang III greater than 
      AngI greater than Ang(1-7) much greater than Ang(1-6). The use of the specific 
      Ang II antagonists CGP 42112A, PD 123177, and DuP 753 revealed that the pancreas 
      expresses two receptor subtypes. The majority of Ang II binding sites in the 
      pancreas could be classified as type 2 (AT2), although type 1 (AT1) sites were 
      also detected. In vitro autoradiography revealed binding sites localized over 
      islet cells, acinar and duct cells, as well as the pancreatic vasculature. In 
      addition, the autoradiographic studies confirmed the predominance of the AT2 
      receptor subtype throughout the pancreas.
FAU - Chappell, M C
AU  - Chappell MC
AD  - Department of Brain and Vascular Research, Cleveland Clinic Foundation, OH 
      44195-5286.
FAU - Diz, D I
AU  - Diz DI
FAU - Jacobsen, D W
AU  - Jacobsen DW
LA  - eng
GR  - HL-38535/HL/NHLBI NIH HHS/United States
GR  - HL-6835/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Peptides
JT  - Peptides
JID - 8008690
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Imidazoles)
RN  - 0 (Oligopeptides)
RN  - 0 (Pyridines)
RN  - 0 (Receptors, Angiotensin)
RN  - 0 (Tetrazoles)
RN  - 11128-99-7 (Angiotensin II)
RN  - 114785-12-5 (PD 123177)
RN  - 127060-75-7 (CGP 42112A)
RN  - 9041-90-1 (Angiotensin I)
RN  - JMS50MPO89 (Losartan)
RN  - T8ID5YZU6Y (Dithiothreitol)
SB  - IM
MH  - Angiotensin I/antagonists & inhibitors/chemistry/drug effects
MH  - Angiotensin II/antagonists & inhibitors/*chemistry/drug effects
MH  - Angiotensin Receptor Antagonists
MH  - Animals
MH  - Binding, Competitive
MH  - Biphenyl Compounds/pharmacology
MH  - Dithiothreitol/pharmacology
MH  - Dogs
MH  - Imidazoles/pharmacology
MH  - Kinetics
MH  - Losartan
MH  - Male
MH  - Oligopeptides/pharmacology
MH  - Pancreas/*chemistry/drug effects/metabolism
MH  - Pyridines/pharmacology
MH  - Receptors, Angiotensin/*chemistry/classification/drug effects
MH  - Tetrazoles/pharmacology
EDAT- 1992/03/01 00:00
MHDA- 1992/03/01 00:01
CRDT- 1992/03/01 00:00
PHST- 1992/03/01 00:00 [pubmed]
PHST- 1992/03/01 00:01 [medline]
PHST- 1992/03/01 00:00 [entrez]
AID - 0196-9781(92)90114-I [pii]
AID - 10.1016/0196-9781(92)90114-i [doi]
PST - ppublish
SO  - Peptides. 1992 Mar-Apr;13(2):313-8. doi: 10.1016/0196-9781(92)90114-i.